Bribery allegations hang over Biomet/Zimmer; FDA clears 31 digital health apps in 2014;

> Bribery allegations in Brazil and Mexico hang over Biomet, tainting its acquisition by Zimmer ($ZMH). The New York Times details the background and how regulators might address them to allow the deal to go forward. Story

> Interleukin Genetics raised $10 million, half in debt and half in equity, to market its genetic tests including one to determine predisposition to severe periodontal disease. The debt is from Horizon Technology Finance ($HRZN), while the equity it from New Enterprise Associates and Bay City Capital. Release

> Sinus dilation player Entellus Medical filed to raise up to $69 million in a public offering, but coronary artery disease test maker CardioDx withdrew its IPO after securing $35M in private financing earlier this week.

> Mobihealthnews has a roundup and analysis of all 31 digital health apps cleared by FDA in 2014. More

> India will now allow foreign companies to acquire India-based medical device companies. Story

> Corgenix Medical ($CONX) received two grants for a total of $818,000 for the development of an Ebola rapid diagnostic kit from the Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation. Release

Suggested Articles

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.

Atomwise and Velocity Pharmaceutical Development co-founded a company to carry AI-derived drugs through preclinical testing and into takeout deals.

Sera Prognostics has raised $36 million in funding to help commercialize its blood test for assessing the risk of premature births.